|
12.02.2015 08:20:50
|
CellaVision Year-end bulletin 2014
Year-end bulletin 2014
Strongest quarter in CellaVision's history and first major veterinary order.
October 1-December 31, 2014
|
January 1-December 31, 2014
| ||
| CEO's comments After being in place for a few weeks I can verify that my first impression of CellaVision as a well-run and flourishing company is correct. I would like to thank Yvonne Mårtensson who, together with all the competent employees, built up the company to what it is today. We have a strong core business and it will be an inspiring challenge to take CellaVision to the next level. It is gratifying that the positive sales trend has been maintained for the sixth quarter in a row. Sales in the quarter were SEK 72.5 million, with sales growth of 12 percent and an operating margin of more than 23 percent. This means that the historically strong fourth quarter of 2013 has now been surpassed. Strong sales growth in EMEA and our first veterinary business are some of the factors behind the sales increase. We also had an advantageous change in the exchange rate for both euro and dollars, which together had a positive impact on earnings for the quarter of more than SEK 5 million. For the full year 2014 growth of 21 percent and an operating margin of 20 percent were achieved, with a positive exchange rate impact on sales of 3 percent. Our sales trend was good, at the same time as work on sound cost control continued to bear fruit. This contributes to our generating a strong cash flow from operating activities of SEK 40 million during the year. CellaVision maintained a high pace of innovation during the year, with the launch of new software for advanced analysis of red blood cells, the CellaVision®Advanced RBC Application and CellaVision® DM9600, which after a somewhat slow start accelerated in terms of sales. | We also increased expansion potential in China through the registration approval from the CFDA for the Sysmex DI-60 and Cellavision® DM1200. We assess that the veterinary segment as limited but see opportunities of more potential business in the future. CellaVision has the potential to add substantial customer value in the veterinary segment by adapting the product portfolio to the needs of the veterinary market. CellaVision's primary focus in this segment lies in the North American market, as it is relatively consolidated, with large veterinary laboratories where sample volumes are high and the need for an effective analysis method great. We have completed the initial pre-study, in collaboration with Clear Lake Medical Foundation, regarding the previously communicated technology acquisition. The objective of expanding our current product portfolio with a platform for small laboratories remains and we are continuing an internal development project. In 2014 a financial outcome was achieved that is the best in the company's history and in acknowledgement of this the Board proposes that the dividend be increased to one krona. CellaVision must have the ambition and curiosity to continually improve patient diagnoses, but also to be more effective, cut costs and remove sources of error in health care. We will achieve continued success by utilizing our core competency in digital image analysis, focusing on hematology. This is a fantastically exciting starting point for me as the new CEO. Zlatko Rihter, President and Chief Executive Officer | ||
| MSEK) | Oct-Dec 2014 | Oct-Dec 2013 | Full year 2014 | Full year 2013 |
| Net sales | 72.5 | 64.9 | 216.9 | 179.9 |
| Gross profit | 50.5 | 39.8 | 145.1 | 112.6 |
| Operating profit | 16.8 | 16.3 | 42.8 | 25.9 |
| Operating margin, % | 23.2 | 25.1 | 19.7 | 14.4 |
| Profit/loss before tax | 16.6 | 16.2 | 43.4 | 24.7 |
| Return on operating capital % | - | - | 62.0 | 45.0 |
| Cash flow for the period | -6.6 | 15.3 | -6.0 | 11.6 |
Questions concerning the report can be addressed to:
Zlatko Rihter, VD, CellaVision AB
Tel: 0733-62 11 06. E-post: zlatko.rihter@cellavision.se
Magnus Blixt, CFO, CellaVision AB
Tel: 0708-33 81 68. E-post: magnus.blixt@cellavision.se
Link text: Cellavision AB Year-end bulletin 2014
This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire
HUG#1893768
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Cellavision ABmehr Nachrichten
|
22.01.25 |
Erste Schätzungen: Cellavision AB veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
|
23.10.24 |
Ausblick: Cellavision AB gewährt Anlegern Blick in die Bücher (finanzen.net) | |
|
09.10.24 |
Erste Schätzungen: Cellavision AB präsentiert Quartalsergebnisse (finanzen.net) |
Analysen zu Cellavision ABmehr Analysen
Aktien in diesem Artikel
| Cellavision AB | 19,48 | 1,88% |
|
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.